ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
New Phase 3 Data Shows Vedolizumab Met Primary Endpoint
americanpharmaceuticalreview
July 24, 2018Takeda announced top-line results from the VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerati
Pharma Sources Insight January 2025
